ImmunityBio (IBRX) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for June 18, 2025, and will be held virtually, with voting available online, by phone, or by mail.

• Stockholders will vote on electing eight directors, approving the 2025 Equity Incentive Plan, and ratifying Deloitte & Touche LLP as the independent auditor for 2025.

• The board recommends voting in favor of all proposals, and the majority stockholder (holding 73.6%) intends to support all items.

Voting matters and shareholder proposals

• Proposals include electing eight directors, approving the 2025 Equity Incentive Plan, and ratifying Deloitte & Touche LLP as auditor.

• The board recommends a vote “FOR” all proposals.

• Only stockholders of record as of April 21, 2025, are entitled to vote.

• Stockholder proposals for the 2026 meeting must be received by January 1, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• The board consists of eight members, five of whom are independent under Nasdaq rules.

• Dr. Patrick Soon-Shiong serves as Executive Chairman; Cheryl L. Cohen is Lead Independent Director.

• The board has Audit, Compensation, Governance, Related Party Transaction, and Special Committees.

• The company is a “controlled company” under Nasdaq rules due to majority ownership by Dr. Soon-Shiong and affiliates.

• Directors are elected annually; the board held seven meetings in 2024, with all directors attending at least 75%.